Equity Overview
Price & Market Data
Price: $2.45
Daily Change: -$0.145 / 5.92%
Daily Range: $2.35 - $2.74
Market Cap: $66,626,748
Daily Volume: 366,895
Performance Metrics
1 Week: -12.13%
1 Month: -13.09%
3 Months: 12.74%
6 Months: 18.32%
1 Year: 9.63%
YTD: 8.64%
Company Details
Employees: 21
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.